Literature DB >> 2322986

Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles.

C Verdun1, F Brasseur, H Vranckx, P Couvreur, M Roland.   

Abstract

The body distribution of i.v. doxorubicin depends mainly on the physicochemical characteristics of the molecule. However, entrapment of that cytostatic drug inside polyalkylcyanoacrylate nanoparticles has been shown to modify its distribution profoundly in the mouse. Polysiohexylcyanoacrylate nanoparticles loaded with [14C]-doxorubicin were studied in comparison with free drug, with emphasis on their distribution pattern in mouse tissue after i.v. administration. An autoradiographic study showed that most of the radioactivity was found in the reticuloendothelial system as soon as a few minutes after i.v. administration of the doxorubicin-loaded nanoparticles. Quantitative determinations by liquid scintillation counting in fresh tissue (spleen, heart, kidneys, liver, lungs, bone marrow) and blood samples confirmed these observations. When the drug was linked to nanoparticles, doxorubicin blood clearance was reduced during the first few minutes after administration, whereas heart and kidney concentrations were substantially decreased. Assays of doxorubicin and doxorubicinol by a specific HPLC analytical method gave results very similar to those obtained by scintillation counting.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322986     DOI: 10.1007/bf02940287

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Studies on the distribution and fate of S35-labelled benzylpenicillin in the body.

Authors:  S ULLBERG
Journal:  Acta Radiol Suppl       Date:  1954

2.  A clinicopathologic analysis of adriamycin cardiotoxicity.

Authors:  E A Lefrak; J Pitha; S Rosenheim; J A Gottlieb
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

3.  Actinomycin D absorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor.

Authors:  F Brasseur; P Couvreur; B Kante; L Deckers-Passau; M Roland; C Deckers; P Speiser
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

4.  Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles.

Authors:  P Couvreur; B Kante; L Grislain; M Roland; P Speiser
Journal:  J Pharm Sci       Date:  1982-07       Impact factor: 3.534

5.  Measurement of adriamycin (doxorubicin) and its metabolites in human plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.

Authors:  R N Pierce; P I Jatlow
Journal:  J Chromatogr       Date:  1979-12-01

6.  Degradation of poly (isobutyl cyanoacrylate) nanoparticles.

Authors:  V Lenaerts; P Couvreur; D Christiaens-Leyh; E Joiris; M Roland; B Rollman; P Speiser
Journal:  Biomaterials       Date:  1984-03       Impact factor: 12.479

7.  Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat.

Authors:  N Willmott; J Cummings; J F Stuart; A T Florence
Journal:  Biopharm Drug Dispos       Date:  1985 Jan-Mar       Impact factor: 1.627

8.  In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells.

Authors:  V Lenaerts; J F Nagelkerke; T J Van Berkel; P Couvreur; L Grislain; M Roland; P Speiser
Journal:  J Pharm Sci       Date:  1984-07       Impact factor: 3.534

9.  Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; D Carmichael; M Harris; J K Roh
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

  9 in total
  12 in total

Review 1.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

2.  Splenic trapping of nanoparticles: complementary approaches for in situ studies.

Authors:  M Demoy; S Gibaud; J P Andreux; C Weingarten; B Gouritin; P Couvreur
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

3.  Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy.

Authors:  S Hariharan; V Bhardwaj; I Bala; J Sitterberg; U Bakowsky; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2006-11-08       Impact factor: 4.200

4.  Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

Authors:  T K Yeung; J W Hopewell; R H Simmonds; L W Seymour; R Duncan; O Bellini; M Grandi; F Spreafico; J Strohalm; K Ulbrich
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles.

Authors:  J Kattan; J P Droz; P Couvreur; J P Marino; A Boutan-Laroze; P Rougier; P Brault; H Vranckx; J M Grognet; X Morge
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

Review 6.  Nanotechnology for delivery of drugs to the brain for epilepsy.

Authors:  Margaret F Bennewitz; W Mark Saltzman
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

7.  Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse.

Authors:  I F Uchegbu; J A Double; J A Turton; A T Florence
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

Review 8.  Nanotechnology in bone tissue engineering.

Authors:  Graham G Walmsley; Adrian McArdle; Ruth Tevlin; Arash Momeni; David Atashroo; Michael S Hu; Abdullah H Feroze; Victor W Wong; Peter H Lorenz; Michael T Longaker; Derrick C Wan
Journal:  Nanomedicine       Date:  2015-03-16       Impact factor: 5.307

Review 9.  Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines.

Authors:  Anil Mahapatro; Dinesh K Singh
Journal:  J Nanobiotechnology       Date:  2011-11-28       Impact factor: 10.435

10.  Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats.

Authors:  Kishore Golla; Bhaskar Cherukuvada; Farhan Ahmed; Anand K Kondapi
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.